Cristina Alburquerque-Prieto

Cristina Alburquerque-Prieto

Auto-generated profile, based on publicly available information

Cristina Alburquerque-Prieto

Servicio de Hematología, Hospital Universitario de Donostia, Donostia, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2023 in Blood
Verified
Journal Article
Closed access
PDF file
IPIrene Peris
Irene Peris
SRSilvia Romero-Murillo
Silvia Romero-Murillo
EBElena Martínez Balsalobre
Elena Martínez Balsalobre
CFCaroline C. Farrington
Caroline C. Farrington
EAElena Arriazu
Elena Arriazu
CVCarmen Vicente
Carmen Vicente
Venetoclax combination therapies are becoming the standard of care in acute myeloid leukemia (AML). However, the therapeutic benefit of these drugs in older/unfit patients is limited to only a few months, highlighting the need for more effective therapies. Protein phosphatase 2A (PP2A) is a tumor suppressor phosphatase with pleiotropic functions that becomes inactivated in ∼70% of AML cases. PP2A promotes cancer cell death by modulating the phosphorylation state in a variety of proteins along the mitochondrial apoptotic pathway. We therefore hypothesized that pharmacological PP2A reactivation could increase BCL2 dependency in AML cells and, thus, potentiate venetoclax–induced cell death. Here, by using 3 structurally distinct PP2A-activating drugs, we show that PP2A reactivation synergistically enhances venetoclax activity in AML cell lines, primary cells, and xenograft models. Through the use of gene editing tools and pharmacological approaches, we demonstrate that the observed therapeutic synergy relies on PP2A complexes containing the B56α regulatory subunit, of which expression dictates response to the combination therapy. Mechanistically, PP2A reactivation enhances venetoclax-driven apoptosis through simultaneous inhibition of antiapoptotic BCL2 and extracellular signal-regulated kinase signaling, with the latter decreasing MCL1 protein stability. Finally, PP2A targeting increases the efficacy of the clinically approved venetoclax and azacitidine combination in vitro, in primary cells, and in an AML patient-derived xenograft model. These preclinical results provide a scientific rationale for testing PP2A-activating drugs with venetoclax combinations in AML.

20 April 2022 in Clinical Case Reports
Verified
Journal Article
Open access
CCCandela Ceballos
Candela Ceballos
CACristina Alburquerque
Cristina Alburquerque
AZAmaya Zabalza
Amaya Zabalza
IQIván Quispe
Iván Quispe
ÁPÁngel Panizo
Ángel Panizo
MMMaría Carmen Mateos
María Carmen Mateos
We report a case based on simultaneous occurrence of Waldenström macroglobulinemia, myeloma and amyloidosis as a collision neoplasm. The strangeness and severity of the case presented a diagnostic and therapeutic challenge, which required individualised treatment and close follow‐up to achieved stringent complete response.

13 August 2026 in Transplantation and Cellular Therapy
Verified
Journal Article
Closed access
SFSara Fernández-Luis
Sara Fernández-Luis
MGMónica Baile González
Mónica Baile González
AAAlejandro Avendaño
Alejandro Avendaño
CACristina Alburquerque-Prieto
Cristina Alburquerque-Prieto
LSLucrecia Yáñez San Segundo
Lucrecia Yáñez San Segundo
IGIrene García-Cadenas
Irene García-Cadenas

2 November 2023 in Blood
Verified
Journal Article
Open access
SFSara Fernández-Luis
Sara Fernández-Luis
ABArancha Bermudez
Arancha Bermudez
LSLucrecia Yanez San Segundo
Lucrecia Yanez San Segundo
MGMónica Baile González
Mónica Baile González
Sara Asensio PeñaSara Asensio Peña
Sara Asensio Peña
ABAnna Maria Sureda Balari
Anna Maria Sureda Balari
Disclosures. Bermudez:GSK: Speakers Bureau; Janssen: Speakers Bureau; Amgen: Speakers Bureau; Pfizer: Speakers Bureau; NEOVII: Speakers Bureau; Sanofi: Speakers